COVID-19 EventAnalyzer

What is the Evaluate COVID-19 EventAnalyzer?

COVID-19 has dominated headlines and triggered market volatility. Given this, Evaluate has decided to share a global roundup of key COVID-19 events driving company valuations.

The Evaluate COVID-19 EventAnalyzer details the largest market valuation gains and losses that can be attributed to COVID-19 initiatives, since the outbreak. It’s a rapid way to identify and understand the listed companies pursuing drug treatments, vaccines or diagnostics for COVID-19.

Check out the Key Covid-19 market movers
Virus Image

Key COVID-19 Market Movers up to 1 April 2020
Company Market Cap Change (US $mln) Market Cap (US $mln) Calculated Share Price Impact (%) EventAnalyzer Note
Johnson & Johnson +25,968 339,589 +8%

COVID-19 Vaccine Development

30 Mar: Selects lead COVID-19 vaccine candidate, expands BARDA co-funding to $1bn; Expects to initiate human trial SEP 2020 latest and anticipates first batch of vaccine for emergency use early 2021. Will establish new US vaccine manufacturing capabilities.

Gilead Sciences +23,118 91,291 +34%

COVID-19 Drug Development: Remdesivir (nucleotide inhibitor)

25 Mar: Shares fall after the company requests FDA to remove orphan drug status for remdesivir, following public disapproval of the decision.

18 Mar: Shares continue to rise. Analyst from Piper Sandler suggests remdesivir could receive regulatory approval 'very soon' off early data.

26 Feb: Company initiates two PIII studies of its antiviral drug, Remdesivir for treatment of COVID-19.

23 Jan: Company reports that it is evaluating its experimental Ebola drug, remdesivir, for the potential treatment of COVID-19.

Roche +21,247 280,935 +8%

COVID-19 Drug Development: Actemra (anti-IL-6 MAb)

04 Mar: China’s National Health Commission recommend use of company's anti-inflammation drug, Actemra for COVID-19 patients with serious lung damage and high IL-6 levels.

COVID-19 Diagnostics Development

16 Mar: Company announces shipping of first 400,000 Cobas SARS-CoV-2 diagnostic tests across US, following granting of FDA Emergency Use Authorisation (EUA).

13 Mar: FDA grants emergency authorization for the company's COVID-19 test, which provides results in three and a half hours.

Sanofi +12,942 107,970 +14%

COVID-19 Drug Development: Kevzara (anti-IL-6 MAb)

30 Mar: Sanofi/Regeneron's Kevzara treats first patient in phase II/III trial.

16 Mar: Initiation of global clinical program for severe COVID-19 infection. PII/PIII trial already initiated in the US and will enroll patients immediately.

10 Mar [post market]: The Wall Street Journal reports plans to evaluate arthritis drug, Kevzara, for the treatment of symptoms of COVID-19.

COVID-19 Vaccine Development

18 Feb: Company to collaborate with BARDA to develop an advanced pre-clinical SARS vaccine for COVID-19 virus.

BioNTech +6,434 12,001 +116%

COVID-19 Vaccine Development: (BNT162)

19 Mar: Shares fall back after rising 38% after string two day gain.

16-18 Mar: Shares rise after announcement of collaboration with Pfizer for WW ex-China and Fosun Pharma for China to develop the company's mRNA vaccine candiate, BNT162, for the prevention of COVID-19 infections on 17 Mar. Plan to initiate clinical trials in late April 2020.

Moderna +5,241 9,762 +116%

COVID-19 Vaccine Development: mRNA-1273 (mRNA vaccine)

16 Mar: Company announces the first participant dosed in the phase I trial of its mRNA-1273 vaccine for COVID-19.

11 Mar: Reuters reports that the company plans to initiate a trial for COVID-19 in collaboration with the National Institutes of Health for 45 people in Seattle this month.

25 Feb: Company to initiate phase I study of its mRNA-1273 for COVID-19 by the end of April.

07 Feb: The USA NIAID (NIH) director states during a White House news conference that the development of the company's COVID-19 vaccine is proceeding well, with hopes to to initiate phase I trials within 2.5 months.

Vir Biotechnology +2,951 3,269 +930%

COVID-19 Drug Development

12 Mar: Company signs a letter of intent with Biogen to develop human monoclonal antibodies for COVID-19 treatment.

COVID-19 Vaccine Development.

11 Mar: Company announces collaboration with the NIH and the National Institute of Allergy and Infectious Diseases (NIAID) to develop antibodies against COVID-19.

25-26 Feb: Company announces collaboration with WuXi Biologics for the global development of antibodies to treat COVID-19.

24 Jan: Shares continue to rise after company announces they are working on a multi-pronged strategy for tackling COVID-19, on 23 Jan.

Takeda +1,908 46,200 +4%

COVID-19 Drug Development: TAK-888 (plasma-derived drug)

05 Mar: Shares rise a day after company announces initiation of development of a plasma-derived drug, TAK-888 for COVID-19, on 4 Mar. TAK-888, is a serum therapy made from the antibodies of recovered COVID-19 patients.

CytoDyn +993 1,442 +221%

COVID-19 Diagnostics Development: Leronlimab (anti-CCR 5 MAb)

30 Mar: Shares rise following news leronlimab used in 3 additional severe COVID-19 cases, bringing the total to 10 treated, with 2 intubated patients able to leave the ICU with reduced pulmonary inflammation.

27 Mar: Files FDA-suggested modifications to IND for PII trial. Positive results have been seen amongst seven COVID-19 patients in New York treated.

29 Jan: Exploring use in COVID-19.

AbbVie +814 108,417 +1%

COVID-19 Drug Development: Kaletra (lopinavir; ritonavir)

06 Feb: Shares rise after a broker report discloses antiretroviral drug Kaletra has become a sought-after antidote for COVID-19.

Amgen -3391 116,670 -3%

COVID-19 Profit Risk

31 Mar: To reduce COVID-19 exposure risk, temporarily pauses enrolment and screening of trials wherever safety and data integrity could become an issue and decides to suspend all in-person meetings and interactions with healthcare company and professionals in US.

AstraZeneca -3884 114,897 -3%

COVID-19 Profit Risk

14 Feb: Company’s Q4’19 revenue misses analyst expectations with collaboration revenue of $414m, a decrease of 36.2% compared to last year. Moreover, company assumes an unfavourable impact on the 2020 financial outlook due to the COVID-19 outbreak in China.

Source: Evaluate, April 2020.
Crowd

You can download the current version of the Evaluate COVID-19 EventAnalyzer data - as seen in the table above - via the form below.

In the meantime, visit our Evaluate COVID-19 Update page for more regular information from our editorially independent Evaluate Vantage team.

Visit the COVID-19 Update

Download the Evaluate COVID-19 EventAnalyzer data set